Skip to content

Arvinas ARVN Change in AR

Change in AR at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$0+100%
Nuvation Bio logo
Nuvation BioNUVB
$6.65M+154%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$0+100%
Merck & Co. logo
Merck & Co.MRK
$272.5M+347%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's change in AR?
Arvinas (ARVN) reported change in AR of $800K in Q1 2026.
How has Arvinas's change in AR changed year-over-year?
Arvinas's change in AR increased by 115.1% year-over-year, from -$5.3M to $800K.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.